GeneTex

  • Country / Location Selection

United States (US)

CIKS peptide

Cat. No. GTX26138

Application

 Neutralizing/Inhibition

Species

 Human
Package
50 μg ($139)
See all CIKS products

APPLICATION

Application Note

WB: GTX26138 will completely block antibody binding in Western blot by incubating the peptide with an equal concentration of antibody for 30 minutes at 37^oC. Optimal dilutions/concentrations should be determined by the end user.

PROPERTIES

Form

Liquid

Buffer

PBS, 0.1% BSA

Preservative

0.02% Sodium azide

Storage

Store the peptide at -20ºC, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.

TARGET

Synonyms

Traf3 Interacting Protein 2 , Act1 , C6Orf2 , C6Orf4 , C6Orf5 , C6Orf6 , Candf8 , Ciks , Psors13 , Traf3Ip2

Background

CIKS (for connection to IKK and SAPK / JNK), also called Act 1 (for NFkappaB Activator 1), is a novel protein that associates with and activates IKK (IkappaB kinase). CIKS / Act1 also activates ATF (Activating Transcription Factor) and AP-1 (Activator Protein 1) through Jun Kinase (JNK). CIKS / Act 1 is ubiquitously expressed in human tissues.

Research Area

REFERENCE

There are currently no references for CIKS peptide (GTX26138). Be the first to share your publications with this product.
Submit a Reference

REVIEW

There are currently no reviews for CIKS peptide (GTX26138). Be the first to share your experience with this product.
Submit a Review
SDS
PBS.pdf
Sodium Azide.pdf
Package List Price ($)
$ 139